Long-term home use of dobutamine in end-stage heart failure in Nigeria: A case report and review of literatures

Edafe E Auchi* and Sotonye T Dodiyi-Manuel

1Department of Internal Medicine, Niger Delta University, Amassoma, Nigeria
2University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

Abstract

Introduction: Dobutamine increases cardiac contractility and causes vasodilation with little change in heart rate. It is used in the management of acute heart failure with cardiogenic shock or in patients with low blood pressure. It has also been documented for use in the management of chronic heart failure. We reported an 86-year-old man with a refractory heart on long term dobutamine.

Case Summary: An 86-year-old retired civil servant living with hypertension for 26 years, type 2 Diabetes Mellitus (T2DM) for 14 years, and hyperlipidemia for 10 years. He was diagnosed with biventricular failure 6 years ago and had cardiac resynchronization therapy (CRT-D) implanted 4 years before the presentation. He presented to the emergency department with 6 weeks history of bilateral leg swelling, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and oliguria. He was treated for NYHA class IV heart failure with digoxin, and dobutamine and furosemide. He was discharged home on long term dobutamine infusion.

Conclusion: Home dobutamine is a simple and effective in term treatment for end-stage heart failure. Its widespread use may be restricted by cost and expertise considerations in Nigeria.

Background

Dobutamine increases cardiac contractility and causes vasodilation with little change in heart rate. It is routinely administered for short periods to relieve exacerbations of congestive heart failure (CHF) in hospitalized patients [3-5]. Sustained effects have been seen with dobutamine infusions, although the known properties of the drug do not explain these effects [6,7]. Long-term dobutamine therapy could lessen the symptoms of CHF and improve exercise tolerance and cardiac function [2,4]. It could be used in patients with refractory heart failure and that awaiting heart transplantation. It also benefits patients with contra-indication to heart transplantation [2,4]. Because the therapy has not been shown to prolong survival in most patients, specific endpoints of therapy could be determined for each patient. Because it may cause sudden death, patients receiving this therapy must be carefully monitored. Long-term use of dobutamine infusion lessens the symptoms of CHF has not been shown to prolong survival but it reduces frequency of hospital admission [4,5].

Outpatient dobutamine infusion for heart failure has not come into a routine practice and prescription in Nigeria medical practice. However, the world being a global village, many of our heart failure patients now travel oversea to seek more advanced medical care in other countries outside Nigeria. They return home after a brief stay of managing the acute condition in those hospitals. At home in Nigeria, they would present to the physicians for continue follow up. Hence, we report this case with review of literature that been on long-term home use of dobutamine in end-stage heart failure from our facility outpatient department in Nigeria.

Case presentation

An 86-year-old retired civil servant who had been living with hypertension for 26 years, type 2 Diabetes Mellitus (T2DM) for 14 years and hyperlipidemia for 10 years. He was diagnosed with biventricular failure 4 ago and had cardiac resynchronization therapy (CRT-D) implanted 3 years ago in a hospital in the United States of America. He presented to the emergency department with 6 weeks history of recurrent bilateral leg swelling with associated dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and oliguria. He has more than 12 repeated hospital admission for heart failure in the past 4 years after the CRT-D. He continued to be admitted every 2 to 3 with gross leg edema, acute pulmonary edema, hypotension, and angina.

At the emergency room, he was noted to be anxious and diaphoretic with a respiratory rate of 36 breaths/minute, not pale, anicteric, no digital clubbing, and bilateral leg edema up to the mid-shin. The chest showed bilateral crepitation in both lung lungs zones. Pulse was 102 beats/minute (diminished in amplitude, and his hands and feet were cool and moist). A summation gallop was noted over the precordium. Fine crepitations were heard over the posterior-basal regions of both lungs. The electrocardiogram showed pacemaker rhythms. He was treated for NYHA class IV heart failure with digoxin, and dobutamine and furosemide. He was discharged home on long term dobutamine infusion.

*Correspondence to: Edafe Emmanuel Auchi, Department of Internal Medicine, Niger Delta University, Amasosa, Nigeria, E-mail: dremmanuedafe@gmail.com

Key words: Dobutamine, refractory heart failure, long term use, home

Received: April 17, 2020; Accepted: April 24, 2020; Published: April 30, 2020
was 80% on room air and 96% on 4 L/min via nasal cannula. The serum sodium 124 mmol/l, potassium 3.9 mmol/l, urea 15 mmol/l (3.2-9 mmol/l), creatine 350 µmol/l. The electrocardiogram showed a pacemaker rhythm. The echocardiography showed an ejection fraction of 28%, dilated four chambers.

Dobutamine (8 mcg/kg/min), sub-cutaneous clexane (0.4 mls), and digoxin (0.125 mg) daily were initially commenced. The blood pressure improved and sustained in the ranged of systolic (120-130 mmHg) and diastolic (80-90 mmHg) on dobutamine. Furosemide 80 mg twice daily was added to the treatment when his blood pressure improved. Dobutamine was later maintained at a dose of 5 µg/kg/minute, with improvement in cardiac output and consequent diuresis. Any attempt to wean him off dobutamine, his clinical condition worsened. He continued on infusion rate with the diluted drug in a dose of 2000 mg in 500 mls of 5% Dextrose water and run 125 mls per day at a rate of 5 drops per minute from Moog Curlin infusion Pump (Curlin Medical) via a Bard pink peripheral venous line with an inline bacterial filter (Figures 1-5). He was discharged self-caring with help from his general practitioner and a nurse. At discharge, he was advised to continue on subcutaneous Lantus 30 IU for his diabetes control, oral metoprolol succinate 50 mg daily, oral spironolactone 25 mg daily, oral furosemide 60 mg twice daily, oral digoxin 0.125 mg daily and regular check of his CRTD.

Follow up

Two months later he was content with his quality of life and able to walk from a car and return to his usual business. He continued to receive continuous dobutamine infusion for over 8 Months with no thrombotic infective complications of treatment with sustained clinical improvement. He has been carrying out his official and home function with no episodes of pulmonary edema or worsening of his heart failure. There has been improvement in exercise tolerance and quality of life, and freedom from hospital admission. Functional improvement from NYHA 4 to 2 in four months.

The patient has been on home dobutamine infusion via a pink peripheral line inserted through the right basilic vein for 7 months.
The peripheral pink link line was changed after 7 months and no complication noted. This home based dobutamine infusion continued till the 9th month when he stated having deterioration in heart failure back to stage 4 NYHA. This he battled with for another 3 months before he died of cardiopulmonary collapse.

Discussion

Dobutamine is a member of the catecholamine family of adrenergic agents. It was formulated to augment ventricular systolic function [8-12]. Dobutamine acts principally through stimulation of β1-adrenergic receptors with lesser stimulation of β2- and α-adrenergic receptors [10,11]. Therefore, dobutamine enhances ventricular contraction with little net direct effect on peripheral vasculature [10,11]. In the setting of human heart failure, the cardiac β1-adrenergic receptors are generally down regulated from chronic stimulation (elevated circulating catecholamines) or blocked by β1-selective adrenergic blockers; most of dobutamine’s hemodynamic effects are then most likely rendered through β2-adrenergic stimulation. In states of ventricular systolic dysfunction, dobutamine increases contractility, stroke volume, and cardiac output [10-11,13].

In the clinical setting with reduced ventricular systolic function, filling pressures, reduced stroke volume and cardiac output, and systemic and organ hypoperfusion, dobutamine increases stroke volume, cardiac output, systemic pressure, and systemic and organ perfusion, and reduces ventricular filling pressures and systemic and pulmonic vascular resistances [10,11,13-16]. Our patient was on Dobutamine to improve the contractility and renal perfusion. Proper dose selection and incrementation achieve these favorable responses without significantly increasing heart rate or provoking other adverse effects [13-14,17-18]. Our patient has not reported any adverse effect of the Dobutamine. He continued till the 9th month at home before the symptoms started deteriorating. He finally passed from cardiopulmonary collapse. The relatively wide separation of positive inotropic and chronotropic effects is an ideal pharmacologic property of an agent intended for short-term therapy of systolic cardiac failure, but this wide separation cannot be maintained for dobutamine if the initial dose is too high [17-20].

Dobutamine also has a favorable effect on ventricular diastolic properties and on ventricular-vascular coupling by reducing aortic impedance [16]. As a positive inotropic agent, dobutamine increases myocardial oxygen consumption [14]. In human low-output cardiac failure, the patient substrate for dobutamine use, this agent increases enterohepatic, renal, and limb blood flow proportional to the augmentation in cardiac output [21-28]. Our patient had better renal perfusion with improvement in urine output, leg edema and reduced hospital admission.

At Ohio State University, long-term dobutamine therapy (typically 5.0-7.5 micrograms/kg/min infused continuously) is used in patients with refractory CHF and that awaiting heart transplantation [29]. Our patient had CRT-D implantation, yet heart failure symptoms persist, and he continued in the part of deterioration and frequent hospital admission before the introduction of long term dobutamine in his management. This necessitates the use of dobutamine infusion. Because the therapy does not prolong survival in most patients, he has benefitted with less hospital admission in the past 8 months. Because it may cause sudden death, patients receiving this therapy must be carefully monitored. Long-term use of dobutamine infusion lessens the symptoms of CHF but does not prolong survival [24-27]. Our patient was on guideline-directed medical therapy and CRTD. Yet, his heart failure continues to deteriorate. In Nigeria, no center is currently offering heart transplantation. Ventricular assist devices such as Tandem Heart and Extracorporeal membrane oxygenation (ECMO) are not available. Our patient has been out of hospital admission for about 8 months while on long term dobutamine infusion.

The main argument against continuous home dobutamine infusion is financial. The drug alone in our case costs approximately 70 thousand naira per week, with other charges for lines, 5%D/W, and syringes plus a degree of home supervision and maintenance of the line. Our patient was able to afford it. The pink peripheral line was changed in our facility under ultrasound guidance and fluoroscopy in a procedure that lasted for 15 to 20 min under local anesthesia. Our patient was saved from protracted hospital hospitalization

Conclusion

Home dobutamine is a simple and effective in term treatment for end-stage heart failure. Its widespread use may be restricted by cost and expertise considerations in Nigeria.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflict of interest

Nil.

References


J Integr Cardiol, 2020 doi: 10.15761/JIC.1000289 Volume 6: 3-4